Nail onychomycosis or fungus infection is caused by a fungus called Trichophyton rubrum and Trichophyton mentagrophytes. However, few cases may also be caused by yeasts and molds. Fungi grow and spread due to conditions of warmth and moisture. The infection begins as a white or yellow spot under the tip of the nail and as it spreads deeper into the nail, it causes potentially painful nail discoloration, thickening, and development of crumbling edges. Onychomycosis commonly affects toenails than in fingernails, as toenails are often confined in a dark, warm, moist environment inside shoes where fungi can thrive. Old age people are more likely to be affected by the disease due to suppressed nail growth and immunity, and other complications.
Grab Sample of this Report at: @
Market Dynamics
Major driver for growth of the dermatophytic onychomycosis treatment market is high prevalence of dermatophytic onychomycosis worldwide. According to a study published in the Journal of the European Academy of Dermatology and Venereology in 2013, the mean prevalence of dermatophytic onychomycosis in Europe and North America was 4.3% in the population-based studies and 8.9% in the hospital-based studies. According to the Centre for Disease Control and Prevention statistics in 2017, around 23 million people in the U.S. are affected by this disease each year.
Increasing geriatric population across the globe is another major factor driving growth of the market. According to the Population Prospects report by the United Nations, the number of people aged 60 years and above would reach 1.3 billion by 2025.
Key features of the study:
This report provides in-depth analysis of dermatophytic onychomycosis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2018 – 2026), considering 2017, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global dermatophytic onychomycosis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc, GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the dermatophytic onychomycosis treatment market
Detailed Segmentation:
Global Dermatophytic Onychomycosis Treatment Market, By Therapy Type:
Systemic Therapy
Topical Therapy
Device-based Therapy
Global Dermatophytic Onychomycosis Treatment Market, By End User:
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
Global Dermatophytic Onychomycosis Treatment Market, By Geography:
North America
By Therapy Type
Systemic Therapy
Topical Therapy
Device-based Therapy
By End Users
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
By Country:
U.S.
Canada
Latin America
By Therapy Type
Systemic Therapy
Topical Therapy
Device-based Therapy
By End Users
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Therapy Type
Systemic Therapy
Topical Therapy
Device-based Therapy
By End Users
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Therapy Type
Systemic Therapy
Topical Therapy
Device-based Therapy
By End Users
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Therapy Type
Systemic Therapy
Topical Therapy
Device-based Therapy
By End Users
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Therapy Type
Systemic Therapy
Topical Therapy
Device-based Therapy
By End Users
Hospitals
Dermatology Clinics
Retail Pharmacies
Others
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Bausch Health Companies *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Novartis AG
Johnson and Johnson
Galderma S.A.,
Anacor Pharmaceuticals
Celtic Pharmaceuticals
GlaxoSmithKline
Pfizer Inc
Moberg Pharma AB
Get Exclusive Discount at: @
“*” marked represents similar segmentation in other categories in the respective section.
Industry Forecast Research 